

To the Press

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

9 January 2014

Exiqon Announces 2014 Grant Program for microRNA, long non-coding RNA or mRNA research

Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") today announced the launch of its 2014 global research grant program, open to researchers from academic and non-profit institutions.

"Exiqon aims to support our customers around the world in their everyday laboratory work and we are proud to offer excellent products for the analysis of any RNA in any biological system. With this grant program we intend to provide access to cutting edge technology and enable scientists to take the next critical step in their RNA research", said Senior Vice President Sales & Marketing, Dr. Henrik M. Pfundheller.

The Exiqon Grant Program has been established with an internal seed funding of 3 grants each worth USD12,500 (EUR 9,000) which will be given to researchers who can best demonstrate how Exiqon can help them accelerate their RNA discoveries.

Recipients will use Exiqon Grant Program awards for the purchase of any of Exiqon's RNA products or services. Exiqon offers a complete product line for RNA investigation, including products for RNA isolation, microRNA microarray analysis, qPCR analysis, Northern Blotting, In Situ Hybridization and functional analysis studies. Exiqon also offers microRNA profiling services based on Next Generation Sequencing, microarray and qPCR analysis, complete with full sample QC and customized data analysis and reporting.

Researchers are invited to submit an application outlining their research area, project goals and proposed workflow no later than **Friday, 31 January 2014**. Award conveyance through the Exiqon Grant Program does not influence, and is not influenced by, any other existing or potential sources of project funding.

Applications must be submitted electronically via a special Grant Program webpage, <http://www.exiqon.com/ls/grants>. Grant recipients will be announced early March 2014.

Additional information:

Additional information is available through Exiqon representatives located across North America and Europe. Interested parties are also invited to contact Exiqon at 1-888-647-2879 (U.S.)/ +45 4566 0888 (EU) or using www.exiqon.com/contact.



About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of microRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of microRNA research products for microRNA analysis in cells. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to develop new medicines based on microRNA as biological markers. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.

